Eli Lilly's Q1 2026 revenues soar 56% YoY, driven by obesity and diabetes drugs, maintaining 'strong buy' rating.

Eli Lilly reported a 56% year-over-year revenue increase in Q1 2026, fueled by strong sales of obesity drug MOUNJARO ($8.66B, +125%) and diabetes drug ZEPBOUND ($4.16B, +80%). The company’s pipeline shows promising progress with the launch of FOUNDAYO and advancements in Retatrutide and Eloralintide. Double-digit growth in EBGLYSS and JAYPIRCA, along with upcoming label expansions, support a $2 billion increase in full-year 2026 revenue guidance. Analyst Terry Chrisomalis maintains a 'strong buy' rating, citing robust growth and multiple near-term clinical and regulatory milestones.